Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nanoviricides Inc
(NY:
NNVC
)
2.290
+0.170 (+8.02%)
Official Closing Price
Updated: 4:10 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanoviricides Inc
< Previous
1
2
3
4
5
6
Next >
NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
February 15, 2024
Via
ACCESSWIRE
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics
February 01, 2024
Via
ACCESSWIRE
A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
January 31, 2024
Colds, flu and RSV aren't the only viral illnesses people have to worry about this winter. A new variant of COVID-19 is rapidly spreading, reminding the world of just how dangerous this virus is.
Via
Benzinga
Exposures
COVID-19
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
January 29, 2024
Via
ACCESSWIRE
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
January 08, 2024
NanoViricides, Inc. (NYSE American: NNVC) recently announced that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco
Via
Benzinga
NanoViricides to Present at the Biotech Showcase in San Fransisco
January 04, 2024
Via
ACCESSWIRE
Is This Ticker That InvestorsObserver Expects To Soar By More Than 350% Next Year On Your Watchlist?
December 01, 2023
--News Direct--
Via
News Direct
Topics
Death
Exposures
COVID-19
Death
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
November 28, 2023
Via
ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
November 15, 2023
Via
ACCESSWIRE
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
November 14, 2023
Via
ACCESSWIRE
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
October 16, 2023
Via
ACCESSWIRE
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
October 12, 2023
Via
ACCESSWIRE
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
October 02, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
September 26, 2023
Read the latest report on NanoViricides here
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 22, 2023
Via
Benzinga
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
August 21, 2023
Via
ACCESSWIRE
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
July 18, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 11, 2023
Via
Benzinga
Why Are NanoViricides Shares Gaining Today
July 11, 2023
NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for
Via
Benzinga
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
July 11, 2023
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Via
News Direct
Exposures
COVID-19
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
July 11, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Exposures
COVID-19
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
July 11, 2023
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday.
Via
Benzinga
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
July 11, 2023
Via
ACCESSWIRE
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
July 10, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
July 06, 2023
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Via
News Direct
Exposures
COVID-19
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
July 06, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Exposures
COVID-19
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
July 06, 2023
Via
ACCESSWIRE
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
July 05, 2023
Read the latest report on NanoViricides here.
Via
Benzinga
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
June 29, 2023
Via
ACCESSWIRE
The 7 Most Promising Penny Stocks to Buy in June
June 07, 2023
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.